Astrazeneca Plc share price today

(AZN)

Astrazeneca Plc share price is $66.3 & ₹5,646.04 as on 25 Dec 2024, 2.30 'hrs' IST

$66.3

▲

-0.33

(-0.5%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Astrazeneca Plc share price in Dollar and Rupees. Guide to invest in Astrazeneca Plc from India. Also see the sentimental analysis on Indian investors investing in Astrazeneca Plc. Get details on the Indian mutual funds that are investing in Astrazeneca Plc. Get Analyst recommendations and forecasts along with all the Astrazeneca Plc's financials.

Astrazeneca Plc share price movements

Today's Low: $65.99
Today's High: $66.63
$66.30
0.48%
Downside
Day's Volatility :0.96%
Upside
0.49%
52 Weeks Low: $60.47
52 Weeks High: $87.68
$66.30
8.79%
Downside
52 Weeks Volatility :31.03%
Upside
24.38%

Astrazeneca Plc Returns

Period	Astrazeneca Plc	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-14.07%	-10.0%	9.4%
6 Months	-15.74%	-5.7%	13.0%
1 Year	0.2%	2.8%	31.8%
3 Years	14.76%	-0.4%	26.3%

Astrazeneca Plc Key Statistics

in dollars & INR

Previous Close	$66.63
Open	$65.93
Today's High	$66.6275
Today's Low	$65.985
Market Capitalization	$202.6B
Today's Volume	$8.2M
52 Week High	$87.675
52 Week Low	$60.47
Revenue TTM	$51.2B
EBITDA	$18.4B
Earnings Per Share (EPS)	$2.07
PE Ratio	31.57
Dividend Yield	2.27%
Profit Margin	12.68%
Quarterly Earnings Growth YOY	0.03%
Return On Equity TTM	16.66%

How to invest in Astrazeneca Plc from India?

It is very easy for Indian residents to invest directly in Astrazeneca Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Astrazeneca Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Astrazeneca Plc or AZN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Astrazeneca Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Astrazeneca Plc shares which would translate to 0.013 fractional shares of Astrazeneca Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Astrazeneca Plc, in just a few clicks!

Returns in Astrazeneca Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Astrazeneca Plc investment value today

Current value as on today

₹1,02,078

Returns

₹2,078

(+2.08%)

Returns from Astrazeneca Plc Stock

₹301 (-0.30%)

Dollar Returns

₹2,379 (+2.38%)

Indian investors sentiment towards Astrazeneca Plc

-40.74%

Period: Sep 25, 2024 to Dec 24, 2024. Change in 30 Days versus previous period

Investment in Astrazeneca Plc from India has reduced in the last 30 days as on Dec 25, 2024. -40.74% less purchase transactions for Astrazeneca Plc in the last 30 days versus the previous period.

-31%

Period: Sep 25, 2024 to Dec 24, 2024. Change in 30 Days versus previous period

Search volume for Astrazeneca Plc on INDmoney from India has reduced in the last 30 days as on Dec 25, 2024. -31% less investors are searching Astrazeneca Plc in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Astrazeneca Plc

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	7544	0.00	0.27%

Global Institutional Holdings in Astrazeneca Plc

T. Rowe Price Associates, Inc.
2.03%
PRIMECAP Management Company
1.35%
Wellington Management Company LLP
1.20%
Capital Research & Mgmt Co - Division 3
1.19%
FMR Inc
0.75%
Franklin Resources Inc
0.62%

Analyst Recommendation on Astrazeneca Plc

Buy

81%Buy

15%Hold

2%Sell

Based on 38 Wall street analysts offering stock ratings for Astrazeneca Plc(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Astrazeneca Plc

What analysts predicted

Upside of 32.75%

Current:

$66.30

Target:

$88.01

Insights on Astrazeneca Plc

Price Movement
In the last 1 month, AZN stock has moved up by 1.5%
Increasing Revenue
AstraZeneca Plc has shown strong revenue growth over the last 7 quarters. The revenue increased from $10.87 billion to $13.56 billion, averaging an increase of 3.6% each quarter.
Decreasing Net Profit
Astrazeneca Plc's net profit has been decreasing over the last four quarters. It started at $2.17 billion and has dropped to $1.42 billion. This represents an average decrease of 12.5% in net profit each quarter.
AZN vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 39.6% return, outperforming this stock by 39.1%
AZN vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 191.6% return, outperforming this stock by 176.0%
Price to Sales
Astrazeneca Plc has a Price-to-Sales Ratio of 24.3, meaning investors are willing to pay $24.3 for every $1 of sales generated by the company. In comparison, Eli Lilly And Company has a lower ratio of 17.6, indicating that investors are paying less for each dollar of sales. This suggests that Astrazeneca is viewed more favorably by investors in terms of its sales performance.

Astrazeneca Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$22.1B	↓ 1.67%
Net Income	$2.2B	↓ 28.19%
Net Profit Margin	9.76%	↓ 3.6%

	FY19	Y/Y Change
Revenue	$24.4B	↑ 10.38%
Net Income	$1.3B	↓ 38.05%
Net Profit Margin	5.47%	↓ 4.29%

	FY20	Y/Y Change
Revenue	$26.6B	↑ 9.16%
Net Income	$3.2B	↑ 139.4%
Net Profit Margin	12.01%	↑ 6.54%

	FY21	Y/Y Change
Revenue	$37.4B	↑ 40.58%
Net Income	$112.0M	↓ 96.5%
Net Profit Margin	0.3%	↓ 11.71%

	FY22	Y/Y Change
Revenue	$44.4B	↑ 18.53%
Net Income	$3.3B	↑ 2835.71%
Net Profit Margin	7.41%	↑ 7.11%

	FY23	Y/Y Change
Revenue	$45.8B	↑ 3.29%
Net Income	$6.0B	↑ 81.11%
Net Profit Margin	13.0%	↑ 5.59%

	Q2 FY23	Q/Q Change
Revenue	$11.4B	↑ 4.94%
Net Income	$1.8B	↑ 0.83%
Net Profit Margin	15.93%	↓ 0.64%

	Q3 FY23	Q/Q Change
Revenue	$11.5B	↑ 0.67%
Net Income	$1.4B	↓ 24.42%
Net Profit Margin	11.96%	↓ 3.97%

	Q4 FY23	Q/Q Change
Revenue	$12.7B	↑ 10.33%
Net Income	$2.2B	↑ 58.59%
Net Profit Margin	17.19%	↑ 5.23%

	Q1 FY24	Q/Q Change
Revenue	$12.9B	↑ 2.04%
Net Income	$1.9B	↓ 11.56%
Net Profit Margin	14.89%	↓ 2.3%

	Q2 FY24	Q/Q Change
Revenue	$12.9B	↑ 0.0%
Net Income	$1.9B	↑ 0.0%
Net Profit Margin	14.89%	↑ 0.0%

	Q3 FY24	Q/Q Change
Revenue	$13.6B	↑ 4.85%
Net Income	$1.4B	↓ 25.84%
Net Profit Margin	10.53%	↓ 4.36%

	FY18	Y/Y Change
Profit	$17.2B	↓ 5.47%

	FY19	Y/Y Change
Profit	$19.5B	↑ 13.46%

	FY20	Y/Y Change
Profit	$21.3B	↑ 9.53%

	FY21	Y/Y Change
Profit	$25.0B	↑ 17.18%

	FY22	Y/Y Change
Profit	$32.0B	↑ 27.94%

	FY23	Y/Y Change
Profit	$37.8B	↑ 18.18%

	Q2 FY23	Q/Q Change
Profit	$9.5B	↑ 5.37%

	Q3 FY23	Q/Q Change
Profit	$9.4B	↓ 0.62%

	Q4 FY23	Q/Q Change
Profit	$9.5B	↑ 1.48%

	Q1 FY24	Q/Q Change
Profit	$9.8B	↑ 2.7%

	Q2 FY24	Q/Q Change
Profit	$9.8B	↑ 0.0%

	Q3 FY24	Q/Q Change
Profit	$10.5B	↑ 7.06%

	FY18	Y/Y Change
Operating Cash Flow	$2.6B	↓ 26.83%
Investing Cash Flow	$963.0M	↓ 141.37%
Financing Cash Flow	$-2.0B	↓ 30.38%

	FY19	Y/Y Change
Operating Cash Flow	$3.0B	↑ 13.41%
Investing Cash Flow	$-657.0M	↓ 168.22%
Financing Cash Flow	$-1.8B	↓ 13.65%

	FY20	Y/Y Change
Operating Cash Flow	$4.8B	↑ 61.64%
Investing Cash Flow	$-285.0M	↓ 56.62%
Financing Cash Flow	$-2.2B	↑ 24.82%

	FY21	Y/Y Change
Operating Cash Flow	$6.0B	↑ 24.26%
Investing Cash Flow	$-11.1B	↑ 3780.0%
Financing Cash Flow	$3.6B	↓ 265.64%

	FY22	Y/Y Change
Operating Cash Flow	$9.8B	↑ 64.48%
Investing Cash Flow	$-3.0B	↓ 73.23%
Financing Cash Flow	$-6.8B	↓ 286.98%

	FY23	Y/Y Change
Operating Cash Flow	$10.3B	↑ 5.48%
Investing Cash Flow	$-4.1B	↑ 37.3%
Financing Cash Flow	$-6.6B	↓ 3.75%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.7B	↓ 45.16%
Investing Cash Flow	$-520.0M	↓ 58.27%
Financing Cash Flow	$-1.5B	↓ 25.21%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$3.1B	↑ 81.26%
Investing Cash Flow	$-1.2B	↑ 134.81%
Financing Cash Flow	$-2.7B	↑ 79.46%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$2.6B	↓ 17.18%
Investing Cash Flow	$-1.1B	↓ 11.79%
Financing Cash Flow	$2.0B	↓ 174.39%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$3.1B	↑ 19.62%
Investing Cash Flow	$-2.4B	↑ 124.05%
Financing Cash Flow	$-1.2B	↓ 160.26%

Astrazeneca Plc Technicals Summary

Sell

Neutral

Buy

Astrazeneca Plc is currently in a neutral trading position according to technical analysis indicators.

Astrazeneca Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Astrazeneca Plc	0.35%	-15.74%	0.2%	14.76%	32.1%
Eli Lilly And Company	5.47%	-11.65%	39.53%	186.01%	505.44%
Johnson & Johnson	-6.75%	-1.06%	-6.96%	-14.38%	-0.33%
Merck & Co. Inc.	-1.77%	-24.43%	-7.67%	29.78%	8.6%
Novo Nordisk A/s	-15.16%	-38.25%	-13.61%	58.94%	204.53%
Abbvie Inc	0.75%	4.23%	15.37%	32.72%	99.99%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Astrazeneca Plc	31.57	31.57	0.71	4.15	0.17	0.09	0.02	26.27
Eli Lilly And Company	85.44	85.44	0.72	13.14	0.65	0.14	0.01	15.83
Johnson & Johnson	23.88	23.88	0.87	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.51	20.51	0.07	7.74	0.28	0.11	0.03	17.58
Novo Nordisk A/s	28.52	28.52	1.27	22.83	0.89	0.21	0.02	27.07
Abbvie Inc	61.39	61.39	0.42	10.94	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Astrazeneca Plc	Buy	$202.6B	32.1%	31.57	12.68%
Eli Lilly And Company	Buy	$716.1B	505.44%	85.44	20.48%
Johnson & Johnson	Buy	$347.8B	-0.33%	23.88	16.74%
Merck & Co. Inc.	Buy	$248.0B	8.6%	20.51	19.23%
Novo Nordisk A/s	Buy	$363.6B	204.53%	28.52	35.01%
Abbvie Inc	Buy	$310.3B	99.99%	61.39	9.22%

Astrazeneca Plc Dividend announcements

Astrazeneca Plc Dividends September, 2024
In the quarter ending September,2024. Astrazeneca Plc has declared dividend of $0.50
Read More

About Astrazeneca Plc

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca Plc has a market cap of $270.68 Billion. It has a P.E ratio of 42.04. The shares of Astrazeneca Plc are trading at $66.63. .

Organization	Astrazeneca Plc
Employees	89900
CEO	Mr. Pascal Soriot D.V.M., M.B.A.
Industry	Health Technology

Management People of Astrazeneca Plc

Name	Title
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Executive Director
Dr. Aradhana Sarin M.D.	CFO & Executive Director
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett	Head of Investor Relations
Mr. Jeffrey Pott J.D.	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina	Head of Global Media Relations
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology Research & Development
Ms. Iskra Reic	Executive Vice President of International
Mr. David Fredrickson	Executive Vice-President of Oncology Business Unit

Important FAQs about investing in Astrazeneca Plc from India :

What is Astrazeneca Plc share price today?

Astrazeneca Plc share price today stands at $66.30, Open: $65.93 ; Previous Close: $66.63 ; High: $66.63 ; Low: $65.99 ; 52 Week High: $87.68 ; 52 Week Low: $60.47. The stock opens at $65.93, after a previous close of $66.63. The stock reached a daily high of $66.63 and a low of $65.99, with a 52-week high of $87.68 and a 52-week low of $60.47.

Can Indians buy Astrazeneca Plc shares?

Yes, Indians can invest in the Astrazeneca Plc (AZN) from India.

With INDmoney, you can buy Astrazeneca Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Astrazeneca Plc at zero transaction cost.

How can I buy Astrazeneca Plc shares from India?

It is very easy to buy Astrazeneca Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Astrazeneca Plc be purchased?

Yes, you can buy fractional shares of Astrazeneca Plc with INDmoney app.

What are the documents required to start investing in Astrazeneca Plc stocks?

To start investing in Astrazeneca Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.